Back to discover
Drug

Fidanacogene elaparvovec

Withdrawn from market
ClassCoagulation factor IX exogenous gene
Also known as Beqvez, Beqvez (115-135 kg), Beqvez (75-95 kg), Beqvez (95-115 kg)+1 more

Beqvez, Beqvez (115-135 kg), Beqvez (75-95 kg), Beqvez (95-115 kg), Beqvez (upto 75 kg).

RxNorm2681011ChEMBLCHEMBL3990034ATCB02BD17UNII413EU9081Y
Coagulation factor IX
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Fidanacogene elaparvovec
Aliases & brands
BeqvezBeqvez (115-135 kg)Beqvez (75-95 kg)Beqvez (95-115 kg)Beqvez (upto 75 kg)
RxNorm CUI
2681011
ChEMBL ID
CHEMBL3990034
ATC codes
B02BD17
UNII
413EU9081Y
Primary mechanism
Coagulation factor IX exogenous gene
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Coagulation factor IX
F9 · P00740
EXOGENOUS GENECoagulation factor IX exogenous gene

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2025-05-15Market withdrawalMarket
Market withdrawal: Beqvez (previously Durveqtix) (EMA)
Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Regulatory event sources are credited in the Regulatory Timeline above.